NCI Drug Dictionary
The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.
- CD40L-Fc fusion protein MEDI 5083
A fusion protein composed of CD40 ligand (CD40L; CD154; TRAP; TNFSF5) fused to a modified immunoglobulin (Ig) Fc fragment, with potential immunostimulating activity. Upon administration of the CD40L-Fc fusion protein MEDI5083, the CD40L moiety specifically targets and binds to and activates CD40, a cell surface receptor that belongs to the tumor necrosis factor (TNF) receptor family and is expressed on various immune cells, such as B lymphocytes, monocytes, and dendritic cells (DCs). Activation of CD40 induces proliferation and activation of B lymphocytes, shifts the induction of suppressive macrophages towards immunostimulatory macrophages, activates monocyte-derived DCs (moDCs), and leads to the secretion of inflammatory cytokines, which activates the immune system to induce the proliferation and activation of cytotoxic T lymphocytes (CTLs) against tumor cells. Altogether, this may cause tumor cell lysis. Check for active clinical trials using this agent. (NCI Thesaurus)
Code name: MEDI 5083